Literature DB >> 6676681

An epidemiological, clinical and microbiological follow-up study of incident meningococcal disease cases in Norway, winter 1981-1982. Material and epidemiology in the MenOPP project.

T W Gedde-Dahl, E A Høiby, A Schillinger, A Lystad, K Bøvre.   

Abstract

To investigate the relative importance of the many possible influencing factors and developmental traits of systemic meningococcal disease (MCd) in the practical Norwegian context, a comprehensive multipurpose case control study was carried out during the winter of 1981-1982 on incident cases in the whole country. The design of the study, the MenOPP project, is outlined. The main inclusion criteria for patients were suspected bacterial meningitis and/or septicemia on referral to hospital. This resulted in 115 verified or probable cases of MCd and 61 patient controls. Randomly drawn from three age strata, 320 population controls were actually approached and 293 (92%) of these responded to the "environmental questionnaire". So did most of the patients (98%). The clinical data mainly comprised information from the commencement of the disease to a sequelae check about six weeks after hospital admission. Laboratory data on strain and serum characteristics were, and still are, collected. The results are to be published in several papers. Here, some epidemiological characteristics of the material are given. Regional, seasonal, and age/sex differences in case fatality are reported and discussed.

Entities:  

Mesh:

Year:  1983        PMID: 6676681

Source DB:  PubMed          Journal:  NIPH Ann        ISSN: 0332-5652


  8 in total

Review 1.  Recognition, treatment and complications of meningococcal disease.

Authors:  F A Riordan; A P Thomson
Journal:  Paediatr Drugs       Date:  1999 Oct-Dec       Impact factor: 3.022

2.  Antibody response in group B meningococcal disease determined by enzyme-linked immunosorbent assay with serotype 15 outer membrane antigen.

Authors:  S Harthug; E Rosenqvist; E A Høiby; T W Gedde-Dahl; L O Frøholm
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

Review 3.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

4.  Variations in case fatality and fatality risk factors of meningococcal disease in Western Norway, 1985-2002.

Authors:  I Smith; A T Bjørnevik; I M B Augland; A Berstad; T Wentzel-Larsen; A Halstensen
Journal:  Epidemiol Infect       Date:  2006-02       Impact factor: 2.451

5.  Binding to human extracellular matrix by Neisseria meningitidis.

Authors:  T Eberhard; R Virkola; T Korhonen; G Kronvall; M Ullberg
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

6.  High case-fatality rates of meningococcal disease in Western Norway caused by serogroup C strains belonging to both sequence type (ST)-32 and ST-11 complexes, 1985-2002.

Authors:  I Smith; D A Caugant; E A Høiby; T Wentzel-Larsen; A Halstensen
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

7.  Use of robotized DNA isolation and real-time PCR to quantify and identify close correlation between levels of Neisseria meningitidis DNA and lipopolysaccharides in plasma and cerebrospinal fluid from patients with systemic meningococcal disease.

Authors:  Reidun Øvstebø; Petter Brandtzaeg; Berit Brusletto; Kari Bente Foss Haug; Knut Lande; Ernst Arne Høiby; Peter Kierulf
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

8.  Extensive Changes in Transcriptomic "Fingerprints" and Immunological Cells in the Large Organs of Patients Dying of Acute Septic Shock and Multiple Organ Failure Caused by Neisseria meningitidis.

Authors:  Berit Sletbakk Brusletto; Else Marit Løberg; Bernt Christian Hellerud; Ingeborg Løstegaard Goverud; Jens Petter Berg; Ole Kristoffer Olstad; Unni Gopinathan; Petter Brandtzaeg; Reidun Øvstebø
Journal:  Front Cell Infect Microbiol       Date:  2020-02-19       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.